Among the most frequently detected oncogenic mutations in NSCLC patients are EGFR-activating mutations, occurring in 10–20% of Caucasians and above 50% in the Asian population, based on the COSMIC database [22] and KRAS (Kirsten rat sarcoma virus) mutations with a frequency of around 30% [23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.